Damora Therapeutics (DMRA) Equity Ratio (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Equity Ratio data on file, last reported at 0.96 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 7.09% year-over-year to 0.96; the trailing twelve-month figure through Mar 2026 stood at 0.96 (up 7.09% YoY), and the FY2025 full-year result was 0.92, changed 0.15% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.96, up from 0.92 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.96 in Q1 2026 and bottomed at 0.74 in Q2 2023.
• The 5-year median for Equity Ratio is 0.87 (2024), against an average of 0.86.
• The widest annual swing landed in 2023, when Equity Ratio retreated 18.88%; it then gained 19.9% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.84 in 2022, then gained by 0.24% to 0.85 in 2023, then climbed by 9.26% to 0.92 in 2024, then slipped by 0.15% to 0.92 in 2025, then increased by 3.56% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.92 (Q4 2025), and 0.75 (Q3 2025), per Business Quant data.

Peer Comparison